Key Highlights

  • Legend Biotech (NASDAQ:LEGN) was down 16.53% in afternoon trading on November 10, 2026 after third-quarter results showed Carvykti net trade sales of about USD 710 million, up 36%.
  • US Carvykti sales grew 19%, while sales outside the US rose 86%, a mix that pointed to slower momentum in the largest market.
  • Total Revenue rose 32% to USD 359.5 million, and the company swung to Net Income of USD 51.7 million, or USD 0.13 per share, from a loss of USD 39.6 million.
  • Cash, equivalents and time deposits stood at about USD 853 million, while Operating Cash Flow was negative USD 35.9 million.

Why Investors Sold

Legend Biotech (NASDAQ:LEGN) shares Carvykti, a CAR-T cell therapy for multiple myeloma, with its partner Johnson & Johnson, and the product's growth rate is the main driver of the stock. The third-quarter increase of 36% was solid, but investors had looked for more after strong earlier quarters, and the 19% growth in the US was much slower than outside it. CAR-T launches are constrained by Manufacturing capacity and by the number of treatment centers able to give the therapy, and a slowdown in the core market raises questions about competition from bispecific antibodies, which can be given off the shelf without cell manufacturing. Investors also noted negative operating cash flow of USD 35.9 million against a positive USD 28.8 million a year earlier, a reminder that the company still consumes cash despite accounting profit. Biotech stocks with high expectations tend to react sharply when growth decelerates, and the drop of 16.53% erased a large part of recent gains. Expectations had risen after a long run of beats, so even a good quarter looked light to some holders.

Progress Behind the Numbers

The quarter still marked real progress. Operating Income was USD 46.8 million against a loss of USD 43.3 million a year earlier, as research spending fell to USD 95.3 million from USD 113.2 million and administrative expense dropped to USD 14.8 million from USD 34.7 million. For the first nine months, revenue reached USD 1.052 billion and net income USD 30.6 million, keeping the company on track for its aim of full-year profitability in 2026. Carvykti is now available at 373 sites in 20 markets. Five-year data from the CARTITUDE-2 study showed half of 20 patients in one cohort alive and progression-free without further therapy, with median progression-free survival of 60.5 months and five-year overall survival of 69.2%. Updated treatment guidelines now favour CAR-T when both CAR-T and T-cell engagers are viable options, a positive for future demand.

Pipeline and Leadership

Ingrid Zhang became chief executive on September 15, 2026, succeeding interim chief Alan Bash, and is tasked with turning Carvykti into a durable profit engine while advancing the pipeline. The company received FDA clearance for LB2501, an in vivo CAR-T candidate targeting CD19 and CD20, which aims to generate CAR-T cells inside the body without complex manufacturing. A US Phase 1/2 trial is planned. For Legend Biotech (NASDAQ:LEGN), US Carvykti demand, manufacturing expansion and early in vivo data will shape sentiment in coming quarters. Legend also continues to ramp manufacturing capacity, which directly limits how many patients can be treated each quarter. Any update on earlier-line approvals for Carvykti would extend the addressable market, and investors will compare each new data point with competing therapies for myeloma. Safety and durability data will stay central to that comparison.

Where Things Stand

Legend Biotech fell 16.53% despite 36% Carvykti growth and a return to profit, as slower US growth of 19% and negative operating cash flow worried investors. The company remains on track for full-year profitability, and long-term data and guideline changes support CAR-T demand. US sales trends and the in vivo CAR-T programme are the next items to watch.